Dynavax Technologies (NASDAQ:DVAX) Earns “Buy” Rating from HC Wainwright

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $31.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 132.47% from the company’s current price.

Other analysts also recently issued reports about the company. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $13.34 on Friday. The stock has a fifty day moving average of $12.81 and a 200 day moving average of $11.99. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of 102.58 and a beta of 1.32. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $13.89.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. As a group, research analysts expect that Dynavax Technologies will post 0.2 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DVAX. E Fund Management Co. Ltd. increased its position in shares of Dynavax Technologies by 4.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 771 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Dynavax Technologies by 7.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 904 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.